` IVX (Invion Ltd) vs S&P/ASX 300 Comparison - Alpha Spread

IVX
vs
S&P/ASX 300

Over the past 12 months, IVX has underperformed S&P/ASX 300, delivering a return of -75% compared to the S&P/ASX 300's 10% growth.

Stocks Performance
IVX vs S&P/ASX 300

Loading
IVX
S&P/ASX 300
Add Stock
www.alphaspread.com

Performance Gap
IVX vs S&P/ASX 300

Loading
IVX
S&P/ASX 300
Difference
www.alphaspread.com

Performance By Year
IVX vs S&P/ASX 300

Loading
IVX
S&P/ASX 300
Add Stock

Competitors Performance
Invion Ltd vs Peers

S&P/ASX 300
IVX
LLY
JNJ
NOVO B
ROG
Add Stock

Invion Ltd
Glance View

Market Cap
9.7m AUD
Industry
Pharmaceuticals

Invion Ltd. is a clinical-stage life sciences company, which engages in the research and development of treatments for market opportunities in a variety of cancer indications, chronic inflammatory, and autoimmune diseases. The company is headquartered in Melbourne, Victoria. The company went IPO on 2010-02-15. The firm is focused on the development of Photosoft technology for the treatment of a range of cancers. The firm is conducting various clinical trials for the development of its Photosoft technology. Its Photo Dynamic Therapy (PDT) is a treatment that optimizes the use of non-toxic photosensitizers and visible light to kill cancer and stimulate the immune system. The firm aims to develop photosensitizer, IVX-PDT, that improves the treatment of skin cancers and hard-to-treat solid cancers, such as those present in ovarian, prostate and lungs. Epitech Dermal Science Pty Ltd is the wholly owned subsidiary of the Company.

IVX Intrinsic Value
0.127 AUD
Undervaluation 2%
Intrinsic Value
Price
Back to Top